Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To determine investigator-assessed progression-free survival (invPFS) by RECIST Version 1.1 for rucaparib versus chemotherapy.
Inclusion criteria
- Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer